Table 1. Baseline characteristics of patients with HFpEF (n = 142).
Continuous variables are given as medians and inter-quartile ranges. Counts are given as numbers and percentages.
| HFpEF patients (n = 142) | |
|---|---|
| Age, median years (IQR) | 71 (66–76) |
| Female gender, n (%) | 99 (70%) |
| BMI, kg/m2 (IQR) | 30 (24–34) |
| Systemic hypertension, n (%) | 139 (98%) |
| Current smokers, n (%) | 55 (39%) |
| Atrial fibrillation, n (%) | 88 (62%) |
| COPD, n (%) | 51 (36%) |
| Diabetes mellitus, n (%) | 52 (37%) |
| Hba1c, % (IQR) | 5.9 (5.6–6.5) |
| NYHA class | |
| NYHA II, n (%) | 42 (30%) |
| NYHA III, n (%) | 87 (61%) |
| NYHA IV, n (%) | 13 (9%) |
| 6-min walking test, meter (IQR) | 330 (240–418) |
| NT-proBNP, ng/L | 1169 (557–2024) |
| Hyperlipidemia, n (%) | 77 (54%) |
| Total cholesterol, mg/dl (IQR) | 169 (144–199) |
| Triglycerides, mg/dl (IQR) | 128 (91–161) |
| Serum creatinine, mg/dl (IQR) | 1.1 (0.9–1.3) |
| GFR, mL/min/1.73 m2 (IQR) | 68 (47–84) |
| C-reactive protein, mg/dl (IQR) | 0.44 (0.2–1.0) |
| Medication | |
| Beta blocker, n (%) | 88 (62%) |
| ACE inhibitor, n (%) | 40 (28%) |
| Calcium channel blocker, n (%) | 40 (28%) |
| Diuretics, n (%) | 91 (64%) |
| Statin, n (%) | 50 (35%) |
BMI–body mass index, COPD–chronic obstructive pulmonary disease, NYHA–New York Heart Association, GFR–glomerular filtration rate, ACE–angiotensin-converting enzyme.